Akero Therapeutics Inc (AKRO)
29.76
-1.21
(-3.91%)
USD |
NASDAQ |
Nov 14, 16:00
29.02
-0.74
(-2.49%)
After-Hours: 20:00
Akero Therapeutics Cash from Investing (Quarterly): 73.07M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 73.07M |
| June 30, 2024 | -255.90M |
| March 31, 2024 | 57.85M |
| December 31, 2023 | 12.79M |
| September 30, 2023 | -125.70M |
| June 30, 2023 | -128.30M |
| March 31, 2023 | 17.59M |
| December 31, 2022 | -101.44M |
| September 30, 2022 | 3.00M |
| June 30, 2022 | 11.87M |
| March 31, 2022 | 22.75M |
| December 31, 2021 | 12.00M |
| September 30, 2021 | 21.93M |
| Date | Value |
|---|---|
| June 30, 2021 | -10.65M |
| March 31, 2021 | 19.00M |
| December 31, 2020 | 17.90M |
| September 30, 2020 | -59.84M |
| June 30, 2020 | 38.46M |
| March 31, 2020 | -6.281M |
| December 31, 2019 | -71.51M |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | -5.00M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-255.90M
Minimum
Jun 2024
73.07M
Maximum
Sep 2024
-22.57M
Average
11.94M
Median
Cash from Investing (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | -202.39M |
| 89bio Inc | -8.639M |
| NovaBay Pharmaceuticals Inc | -0.002M |
| Palatin Technologies Inc | -0.0049M |
| iBio Inc | -0.144M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -70.42M |
| Cash from Financing (Quarterly) | 3.067M |
| Free Cash Flow | -212.64M |
| Free Cash Flow Per Share (Quarterly) | -1.014 |
| Free Cash Flow Yield | -11.27% |